Ecr Reductive Aldol Biocatalysis for α-Branched β′-Hydroxy Carbonyls
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing reductive aldol reactions in synthetic chemistry face challenges due to the use of expensive hydrosilanes and scarce transition metals, leading to unwanted adducts and requiring enantiomerically pure organo ligands, while biocatalysts for stereoselective reactions under mild and sustainable conditions are lacking.
Innovation Solution
Employing enoyl-CoA carboxylase/reductases (Ecrs) for enzymatic-catalyzed reductive aldol reactions using α,β-unsaturated carbonyl donors and carbonyl acceptors, replacing the native CO2 electrophile with different carbonyl acceptors to form α-branched β′-hydroxy carbonyl compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If hydrosilanes are used as reductants in reductive aldol reactions, then the reaction can proceed, but the cost increases and unwanted silyl ether adducts are formed
Solution Approach 1:
The patent replaces expensive hydrosilane reductants with a biological reductase enzyme system that uses inexpensive reducing equivalents from the cellular metabolism (such as NADPH). This substitution eliminates the formation of unwanted silyl ether adducts while maintaining reaction feasibility through enzymatic catalysis.
Solution Approach 2:
The patent substitutes the chemical reductant system (hydrosilanes) with a biological enzyme system (reductase). This replacement transitions from a purely chemical approach to a bio-catalytic approach, where the enzyme provides stereoselectivity and avoids side reactions that produce unwanted adducts.
2Manufacturing precision
If transition metals are used as catalysts for diastereomer- and enantioselective C—C couplings, then selectivity is achieved, but the cost increases and enantiomerically pure organo ligands are required
Solution Approach 1:
The patent replaces expensive transition metal catalysts requiring enantiomerically pure organo ligands with a biological reductase enzyme. The enzyme inherently provides the necessary stereoselectivity through its chiral active site, eliminating the need for costly metal-ligand complexes while achieving the same manufacturing precision for diastereomer- and enantioselectivity.
Solution Approach 2:
The patent substitutes transition metal-based catalysis with enzyme-based biocatalysis. The biological system provides inherent stereoselectivity through the chiral environment of the enzyme's active site, replacing the need for carefully designed metal-ligand systems while reducing costs and simplifying the process.
3Productivity
If conventional reductive aldol reactions are used, then C—C coupling can be achieved, but stereoselective reactions under mild and sustainable conditions are not available
Solution Approach 1:
The patent replaces conventional chemical reductive aldol reactions with an enzyme-catalyzed version. The biological reductase enzyme enables the reaction to proceed under mild physiological conditions while providing inherent stereoselectivity, thus achieving both productivity and adaptability that conventional methods cannot simultaneously provide.
Solution Approach 2:
The patent changes the reaction conditions from conventional chemical parameters to biological parameters. By using an enzyme system, the reaction occurs under mild conditions (physiological temperature, pH, and aqueous environment) while maintaining high stereoselectivity through the enzyme's chiral catalysis, thus expanding the versatility of the reaction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables stereoselective reductive aldol reactions with high turnover frequency and yield, allowing the synthesis of complex compounds with improved diastereomeric ratios and expanding the scope of enzyme-catalyzed transformations for synthetic biology and organic synthesis.
Implementation Method 1
enoyl-CoA carboxylase/reductases (Ecrs) for enzymatic-catalyzed reductive aldol reactions
Implementation Method 2
reductive aldol reactions by reacting α,β-unsaturated carbonyl donors with carbonyl acceptors in the presence of a polypeptide capable of catalyzing reductive aldol reactions and a cofactor
Data Source
AI summary
The present invention relates to a method for preparing α-branched β′-hydroxy carbonyl compounds through enzymatic-catalyzed reductive aldol reaction by reacting α,β-unsaturated carbonyl donors with carbonyl acceptors in the presence of a polypeptide capable of catalyzing reductive aldol reactions and a cofactor, wherein the polypeptide is an enoyl-CoA carboxylase/reductase (Ecr). The replacement of the native CO2 electrophile in enoyl-CoA carboxylases/reductases (Ecrs) by different carbonyl acceptors advantageously creates a new-to-nature biocatalytic route towards α-branched β′-hydroxy carbonyl compounds.